Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity

Details for Australian Patent Application No. 2008323390 (hide)

Owner H. Lundbeck A/S Takeda Pharmaceuticals North America, Inc

Inventors Batra, Aneil; Dragheim, Marianne; Moore, Nicholas; Chon, Jin

Agent Watermark

Pub. Number AU-A-2008323390

PCT Pub. Number WO2009/062517

Priority 61/097,840 17.09.08 US; 61/013,722 14.12.07 US; 60/987,710 13.11.07 US; PA 200701788 14.12.07 DK; PA 200701607 13.11.07 DK; PA 200801300 17.09.08 DK

Filing date 12 November 2008

Wipo publication date 22 May 2009

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

Event Publications

3 June 2010 PCT application entered the National Phase

  PCT publication WO2009/062517 Priority application(s): WO2009/062517

22 July 2010 Amendment Made

  The nature of the amendment is: Delete priority details under INID (31) 61/097,840; 61/013,722; 60/987,710

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008323454-Ultrasonic medicine paste

2008323387-An actuator system